Coated edible plant-derived microvesicle compositions and methods for using the same

Abstract

Compositions are provided that comprise a microvesicle derived from an edible plant. The microvesicles are coated with a plasma membrane derived from a targeting cell and can further be utilized to encapsulate a therapeutic agent. Methods for treating an inflammatory disorder and/or a cancer are further provided and include the step of administering to a subject an effective amount of a composition that includes a microvesicle coated with a plasma membrane derived from a targeting cell.

1 . A composition, comprising:
 a microvesicle derived from an edible plant; and   a plasma membrane coating the microvesicle, the plasma membrane derived from a targeting cell.   
     
     
         2 . The composition of  claim 1 , wherein the microvesicle encapsulates a therapeutic agent. 
     
     
         3 . The composition of  claim 1 , wherein the targeting cell is an activated leukocyte. 
     
     
         4 . The composition of  claim 1 , wherein the edible plant is a fruit or a vegetable. 
     
     
         5 . The composition of  claim 1 , wherein the fruit is selected from a grape, a grapefruit, and a tomato. 
     
     
         6 . The composition of  claim 2 , wherein the therapeutic agent is selected from a phytochemical agent and a chemotherapeutic agent. 
     
     
         7 . The composition of  claim 6 , wherein the therapeutic agent is a phytochemical agent, and wherein the phytochemical agent is selected from curcumin, resveratrol, baicalein, equol, fisetin, and quercetin. 
     
     
         8 . The composition of  claim 6 , wherein the therapeutic agent is a chemotherapeutic agent, and wherein the chemotherapeutic agent is selected from the group consisting of retinoic acid, 5-fluorouracil, vincristine, actinomycin D, adriamycin, cisplatin, docetaxel, doxorubicin, and taxol. 
     
     
         9 . The composition of  claim 1 , wherein the therapeutic agent comprises a nucleic acid molecule selected from an siRNA, a microRNA, and a mammalian expression vector. 
     
     
         10 . A pharmaceutical composition, comprising a composition according to  claim 1  and a pharmaceutically-acceptable vehicle, carrier, or excipient. 
     
     
         11 . A method for treating an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a composition of  claim 1 . 
     
     
         12 . The method of  claim 11 , wherein the inflammatory disorder is selected from the group consisting of sepsis, septic shock, colitis, colon cancer, and arthritis. 
     
     
         13 . The method of  claim 11 , wherein the composition is administered orally or intransally. 
     
     
         14 . The method of  claim 11 , wherein administering the composition reduces an amount of an inflammatory cytokine in a subject. 
     
     
         15 . The method of  claim 14 , wherein the inflammatory cytokine is selected from the group consisting of tumor necrosis factor-α, interleukin-1β, interferon γ, and interleukin-6. 
     
     
         16 . The method of  claim 11 , wherein the edible plant is a fruit or a vegetable. 
     
     
         17 . The method of  claim 16 , wherein the fruit is selected from a grape, a grapefruit, and a tomato. 
     
     
         18 . The method of  claim 11 , wherein the microvesicle encapsulates a therapeutic agent, and wherein the therapeutic agent is a phytochemical agent. 
     
     
         19 . The method of  claim 18 , wherein the phytochemical agent is curcumin. 
     
     
         20 . The method of  claim 11 , wherein the inflammatory disorder is colitis. 
     
     
         21 . A method for treating a cancer in a subject, comprising administering to a subject an effective amount of a composition according to  claim 1 . 
     
     
         22 . The method of  claim 21 , wherein the microvesicle encapsulates a therapeutic agent, and wherein the therapeutic agent is selected from a phytochemical agent and a chemotherapeutic agent. 
     
     
         23 . The method of  claim 21 , wherein the cancer is selected from a brain cancer, a breast cancer, a lung cancer, and a colon cancer.